Report findsĀ nirsevimabĀ 80% effective at preventing RSV-associatedĀ ICU admissionsĀ
Nirsevimab was found to be 80% effective at preventing respiratory syncytial virus-associated intensive care unit admissions during the 2024-2025 RSV season, according to a Centers for Disease Control and Prevention report released Nov. 20. It also found the treatment to be 83% effective at preventing acute respiratory failure among infants admitted to an ICU with symptoms during their first RSV season. āThese estimates support the recommendation for use of nirsevimab as a prevention strategy to protect infants against severe outcomes from RSV infection,ā the CDC said.
Related News Articles
Perspective
May is Mental Health Awareness Month, a time to elevate a conversation that hospitals and health systems live every day. Behavioral health is inseparable fromā¦
Headline
The Agency for Healthcare Research and Quality has issued a request for nominations for candidates to serve on the U.S. Preventive Services Task Force. Whileā¦
Headline
Obesity rates for U.S. children and teenagers have reached record highs, while rates for adults had a slight decline, according to reports by the Centers forā¦
Blog
The holiday season is often depicted as a time of joy and celebration, but for health care professionals it can also be a busy and emotionally demanding timeā¦
Headline
The Advisory Committee on Immunization Practices Dec. 5 recommended individual-based decision-making for parents deciding whether to give the hepatitis Bā¦
Blog
Even before the COVID pandemic, the mental health and wellness of our young people was failing. The pandemic exacerbated the crisis and made it difficult forā¦